Role of corticotropin-releasing factor family peptides and receptors in stress-related psychiatric disorders

Seminars in Clinical Neuropsychiatry

Volumn 8, Issue 2, 2003, Pages 119-136

  Clark, Michael S ^a   Kaiyala, Karl J ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE; UROCORTIN;

ANXIETY; DEPRESSION; DRUG DEPENDENCE; FEEDING BEHAVIOR; HUMAN; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; PROTEIN FAMILY; PROTEIN LOCALIZATION; REVIEW; STRESS; SUBSTANCE ABUSE; BINDING SITE; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

BINDING SITES; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MENTAL DISORDERS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL;

EID: 0038578142     PISSN: 10843612     EISSN: None     Source Type: Journal    
DOI: 10.1053/scnp.2003.50011     Document Type: Review

References (217)

1. Kaufman J, Charney D: Effects of early stress on brain structure and function: implications for understanding the relationship between child maltreatment and depression. Dev Psychopathol 13:451-471, 2001
2. Gorman JM, Mathew S, Coplan J: Neurobiology of early life stress: nonhuman primate models. Semin Clin Neuropsychiatry 7:96-103, 2002
3. Plotsky PM, Meaney MJ: Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res 18:195-200, 1993
4. Heim C, Nemeroff CB: Neurobiology of early life stress: clinical studies. Semin Clin Neuropsychiatry 7:147-159, 2002
5. Pine DS, Cohen JA: Trauma in children and adolescents: risk and treatment of psychiatric sequelae. Biol Psychiatry 51:519-531, 2002
6. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12, 1999
7. Price ML, Kirby LG, Valentino RJ, Lucki I: Evidence for corticotropin-releasing factor regulation of serotonin in the lateral septum during acute swim stress: adaptation produced by repeated swimming. Psychopharmacology (Berl) 162:406-414, 2002
8. Price ML, Curtis AL, Kirby LG, Valentino RJ, Lucki I: Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 18:492-502, 1998
9. Koob GF: Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46:1167-1180, 1999
10. Asbach S, Schulz C, Lehnert H: Effects of corticotropin-releasing hormone on locus coeruleus neurons in vivo: a microdialysis study using a novel bilateral approach. Eur J Endocrinol 145:359-363, 2001
11. Valentino RJ, Curtis AL, Page ME, Pavcovich LA, Florin-Lechner SM: Activation of the locus ceruleus brain noradrenergic system during stress: circuitry, consequences, and regulation. Adv Pharmacol 42:781-784, 1998
12. Gold PW, Chrousos GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 7:254-275, 2002
13. Adamec R, Kent P, Anisman H, Shallow T, Merali Z: Neural plasticity, neuropeptides and anxiety in animals - implications for understanding and treating affective disorder following traumatic stress in humans. Neurosci Biobehav Rev 23:301-318, 1998
14. Adamec RE, Shallow T: Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav 54:101-109, 1993
15. Kasckow JW, Baker D, Geracioti TD Jr: Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 22:845-851, 2001
16. Yehuda R: Biology of posttraumatic stress disorder. J Clin Psychiatry 62:41-46, 2001 (suppl 17)
17. Heim C, Nemeroff CB: The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 49:1023-1039, 2001
18. Weiss F, Ciccocioppo R, Parsons LH, et al: Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 937:1-26, 2001
19. Radulovic J, Ruhmann A, Liepold T, Spiess J: Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19:5016-5025, 1999
20. Negri L, Noviello L, Noviello V: Effects of sauvagine, urotensin I and CRF on food intake in rats. Peptides 6:53-57, 1985 (suppl 3)
21. Krahn DD, Gosnell BA, Grace M, Levine AS: CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res Bull 17:285-289, 1986
22. Dautzenberg FM, Hauger RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71-77, 2002
23. Dautzenberg FM, Kilpatrick GJ, Hauger RL, Moreau J: Molecular biology of the CRH receptors - in the mood. Peptides 22:753-760, 2001
24. Reul JM, Holsboer F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23-33, 2002
25. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394-1397, 1981
26. Spiess J, Rivier J, Rivier C, Vale W: Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A 78:6517-6521, 1981
27. Skofitsch G, Jacobowitz DM: Distribution of corticotropin releasing factor-like immunoreactivity in the rat brain by immunohistochemistry and radioimmunoassay: comparison and characterization of ovine and rat/human CRF antisera. Peptides 6:319-336, 1985
28. Joseph SA, Pilcher WH, Knigge KM: Anatomy of the corticotropin-releasing factor and opiomelanocortin systems of the brain. Fed Proc 44:100-107, 1985
29. Swanson LW, Sawchenko PE, Rivier J, Vale WW: Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36:165-186, 1983
30. Sakanaka M, Shibasaki T, Lederis K: Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex. Brain Res 382:213-238, 1986
31. Shimada S, Inagaki S, Kubota Y, Ogawa N, Shibasaki T, Takagi H: Coexistence of peptides (corticotropin releasing factor/neurotensin and substance P/somatostatin) in the bed nucleus of the stria terminalis and central amygdaloid nucleus of the rat. Neuroscience 30:377-383, 1989
32. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, et al: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292, 1995
33. Zhao L, Donaldson CJ, Smith GW, Vale WW: The structures of the mouse and human urocortin genes (Ucn and UCN). Genomics 50:23-33, 1998
34. Cepoi D, Sutton S, Arias C, Sawchenko P, Vale WW: Ovine genomic urocortin: cloning, pharmacologic characterization, and distribution of central mRNA. Brain Res Mol Brain Res 68:109-118, 1999
35. Donaldson CJ, Sutton SW, Perrin MH, et al: Cloning and characterization of human urocortin. Endocrinology 137:2167-2170, 1996
36. Reyes TM, Lewis K, Perrin MH, et al: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98:2843-2848, 2001
37. Hsu SY, Hsueh AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605-611, 2001
38. Lewis K, Li C, Perrin MH, et al: Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 98:7570-7575, 2001
39. Merchenthaler I, Vigh S, Petrusz P, Schally AV: Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat 165:385-396, 1982
40. Merchenthaler I, Vigh S, Petrusz P, Schally AV: The paraventriculo-infundibular corticotropin releasing factor (CRF) pathway as revealed by immunocytochemistry in long-term hypophysectomized or adrenalectomized rats. Regul Pept 5:295-305, 1983
41. Merchenthaler I: Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 5:53-69, 1984 (suppl 1)
42. Merchenthaler I, Vigh S, Schally AV, Stumpf WE, Arimura A: Immunocytochemical localization of corticotropin releasing factor (CRF)-like immunoreactivity in the thalamus of the rat. Brain Res 323:119-122, 1984
43. Petrusz P, Merchenthaler I, Maderdrut JL, Heitz PU: Central and peripheral distribution of corticotropin-releasing factor. Fed Proc 44:229-235, 1985
44. Sawchenko PE, Swanson LW: Localization, colocalization, and plasticity of corticotropin-releasing factor immunoreactivity in rat brain. Fed Proc 44:221-227, 1985
45. Sakanaka M, Shibasaki T, Lederis K: Corticotropin releasing factor-like immunoreactivity in the rat brain as revealed by a modified cobalt-glucose oxidase-diaminobenzidine method. J Comp Neurol 260:256-298, 1987
46. Davis M, Walker DL, Lee Y: Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann N Y Acad Sci 821:305-331, 1997
47. Davis M, Whalen PJ: The amygdala: vigilance and emotion. Mol Psychiatry 6:13-34, 2001
48. Davis M, Shi C: The amygdala. Curr Biol 10:R131, 2000
49. Davis M, Walker DL, Lee Y: Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philos Trans R Soc Lond B Biol Sci 352:1675-1687, 1997
50. Valentino RJ, Van Bockstaele E: Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Potential for reciprocal interactions between stress and opioid sensitivity. Psychopharmacology (Berl) 158:331-342, 2001
51. Francis DD, Caldji C, Champagne F, Plotsky PM, Meaney MJ: The role of corticotropin-releasing factor - norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress. Biol Psychiatry 46:1153-1166, 1999
52. Kawata M, Hashimoto K, Takahara J, Sano Y: Differences in the distributional pattern of CRF-, oxytocin-, and vasopressin-immunoreactive nerve fibers in the median eminence of the rat. Cell Tissue Res 230:247-258, 1983
53. Price ML, Lucki I: Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor. J Neurosci 21:2833-2841, 2001
54. Boadle-Biber MC, Singh VB, Corley KC, Phan TH, Dilts RP: Evidence that corticotropin-releasing factor within the extended amygdala mediates the activation of tryptophan hydroxylase produced by sound stress in the rat. Brain Res 628:105-114, 1993
55. Phelix CF, Liposits Z, Paull WK: Serotonin-CRF interaction in the bed nucleus of the stria terminalis: a light microscopic double-label immunocytochemical analysis. Brain Res Bull 28:943-948, 1992
56. Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE: Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J Comp Neurol 415:285-312, 1999
57. Skelton KH, Nemeroff CB, Knight DL, Owens MJ: Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20:1240-1248, 2000
58. Bachtell RK, Wang YM, Freeman P, Risinger OF, Ryabinin AE: Alcohol drinking produces brain region-selective changes in expression of inducible transcription factors. Brain Res 847:157-165, 1999
59. Bachtell RK, Tsivkovskaia NO, Ryabinin AE: Strain differences in urocortin expression in the Edinger-Westphal nucleus and its relation to alcohol-induced hypothermia. Neuroscience 113:421-434, 2002
60. Wong ML, al-Shekhlee A, Bongiorno PB, et al: Localization of urocortin messenger RNA in rat brain and pituitary. Mol Psychiatry 1:307-312, 1996
61. Yamamoto H, Maeda T, Fujimura M, Fujimiya M: Urocortin-like immunoreactivity in the substantia nigra, ventral tegmental area and Edinger-Westphal nucleus of rat. Neurosci Lett 243:21-24, 1998
62. Kozicz T, Yanaihara H, Arimura A: Distribution of urocortin-like immunoreactivity in the central nervous system of the rat. J Comp Neurol 391:1-10, 1998
63. Li C, Vaughan J, Sawchenko PE, Vale WW: Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 22:991-1001, 2002
64. Lovenberg TW, Chalmers DT, Liu C, De Souza EB: CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136:4139-4142, 1995
65. Chen R, Lewis KA, Perrin MH, Vale WW: Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90:8967-8971, 1993
66. Chalmers DT, Lovenberg TW, De Souza EB: Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15:6340-6350, 1995
67. Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW: Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 133:3058-3061, 1993
68. Kishimoto T, Pearse RV II, Lin CR, Rosenfeld MG: A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A 92:1108-1112, 1995
69. Liaw CW, Lovenberg TW, Barry G, Oltersdorf T, Grigoriadis DE, de Souza EB: Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137:72-77, 1996
70. Lovenberg TW, Liaw CW, Grigoriadis DE, et al: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 92:836-840, 1995
71. Bittencourt JC, Sawchenko PE: Do centrally administered neuropeptides access cognate receptors? An analysis in the central corticotropin-releasing factor system. J Neurosci 20:1142-1156, 2000
72. Van Pett K, Viau V, Bittencourt JC, et al: Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191-212, 2000
73. Gulyas J, Rivier C, Perrin M, et al: Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A 92:10575-10579, 1995
74. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J: Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A 95:15264-15269, 1998
75. Lawrence AJ, Krstew EV, Dautzenberg FM, Ruhmann A: The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br J Pharmacol 136:896-904, 2002
76. Ruhmann A, Chapman J, Higelin J, Butscha B, Dautzenberg FM: Design, synthesis and pharmacological characterization of new highly selective CRF(2) antagonists: development of 1231-K31440 as a potential SPECT ligand. Peptides 23:453-460, 2002
77. Higelin J, Py-Lang G, Paternoster C, Ellis GJ, Patel A, Dautzenberg FM: 1251-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology 40:114-122, 2001
78. Chrousos GP, Calabrese JR, Avgerinos P, et al: Corticotropin releasing factor: basic studies and clinical applications. Prog Neuropsychopharmacol Biol Psychiatry 9:349-359, 1985
79. Schulz DW, Mansbach RS, Sprouse J, et al: CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93:10477-10482, 1996
80. Griebel G, Simiand J, Steinberg R, et al: 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotropin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345, 2002
81. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE: Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202, 2002
82. McCarthy JR, Heinrichs SC, Grigoriadis DE: Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 5:289-315, 1999
83. Okuyama S, Chaki S, Kawashima N, et al: Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289:926-935, 1999
84. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP: In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137:5747-5750, 1996
85. Arvanitis AG, Gilligan PJ, Chorvat RJ, et al: Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J Med Chem 42:805-818, 1999
86. Gilligan PJ, Baldauf C, Cocuzza A, et al: The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1, 5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg Med Chem 8:181-189, 2000
87. Keller C, Bruelisauer A, Lemaire M, Enz A: Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab Dispos 30:173-176, 2002
88. Zobel AW, Nickel T, Kunzel HE, et al: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181, 2000
89. Petraglia F, Florio P, Gallo R, et al: Corticotropin-releasing factor-binding protein: origins and possible functions. Horm Res 45:187-191, 1996
90. Petraglia F, Potter E, Cameron VA, et al: Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J Clin Endocrinol Metab 77:919-924, 1993
91. Behan DP, Potter E, Sutton S, Fischer W, Lowry PJ, Vale WW: Corticotropin-releasing factor-binding protein. A putative peripheral and central modulator of the CRF family of neuropeptides. Ann N Y Acad Sci 697:1-8, 1993
92. Rosendale BE, Jarrett DB, Robinson AG: Identification of a corticotropin-releasing factor-binding protein in the plasma membrane of AtT-20 mouse pituitary tumor cells and its regulation by dexamethasone. Endocrinology 120:2357-2366, 1987
93. Seasholtz AF, Burrows HL, Karolyi IJ, Camper SA: Mouse models of altered CRH-binding protein expression. Peptides 22:743-751, 2001
94. Henriot S, Dautzenberg FM, Kilpatrick GJ: Urocortin: slower dissociation than corticotropin releasing factor from the CRF binding protein. Eur J Pharmacol 376:321-324, 1999
95. Behan DP, Grigoriadis DE, Lovenberg T, et al: Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry 1:265-277, 1996
96. Behan DP, Heinrichs SC, Troncoso JC, et al: Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature 378:284-287, 1995
97. Zorrilla EP, Schulteis G, Ling N, Koob GF, De Souza EB: Performance-enhancing effects of CRF-BP ligand inhibitors. Neuroreport 12:1231-1234, 2001
98. Kemp CF, Woods RJ, Lowry PJ: The corticotrophin-releasing factor-binding protein: an act of several parts. Peptides 19:1119-1128, 1998
99. Hollander CS, Audhya T, Nakane T, et al: Distribution, biosynthesis, and physiological role of corticotropin-releasing factor in the human: an overview. Trans Assoc Am Physicians 96:122-130, 1983
100. Scoggins BA, Coghlan JP, Denton DA, et al: The effect of intracerebroventricular infusions of CRF, sauvagine, ACTH (1-24) and ACTH (4-10) on blood pressure in sheep. J Hypertens Suppl 2:S67-S68, 1984
101. Brown MR, Fisher LA, Rivier J, Spiess J, Rivier C, Vale W: Corticotropin-releasing factor: effects on the sympathetic nervous system and oxygen consumption. Life Sci 30:207-210, 1982
102. Cole BJ, Koob GF: Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J Pharmacol Exp Ther 247:902-910, 1988
103. Berridge CW, Dunn AJ: Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice. Regul Pept 16:83-93, 1986
104. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT: CRF antagonist reverses the anxiogenic response to ethanol withdrawal in the rat. Psychopharmacology 103:227-232, 1991
105. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale W: Corticotropin releasing factor produces behavioural activation in rats. Nature 297:331-333, 1982
106. Imaki T, Shibasaki T, Hotta M, Demura H: Intracerebroventricular administration of corticotropin-releasing factor induces c-fos mRNA expression in brain regions related to stress responses: comparison with pattern of c-fos mRNA induction after stress. Brain Res 616:114-125, 1993
107. Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, De Souza EB: The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res 770:89-95, 1997
108. Contarino A, Dellu F, Koob GF, et al: Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology 141:2698-2702, 2000
109. Smith GW, Aubry JM, Dellu F, et al: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102, 1998
110. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF: Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 22:193-199, 2002
111. Pelleymounter MA, Joppa M, Ling N, Foster AC: Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302:145-152, 2002
112. Weninger SC, Dunn AJ, Muglia LJ, et al: Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci U S A 96:8283-8288, 1999
113. Smagin GN, Swiergiel AH, Dunn AJ: Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res Bull 36:71-76, 1995
114. Rassnick S, Hoffman GE, Rabin BS, Sved AF: Injection of corticotropin-releasing hormone into the locus coeruleus or foot shock increases neuronal Fos expression. Neuroscience 85:259-268, 1998
115. Curtis AL, Grigoriadis DE, Page ME, Rivier J, Valentino R J RJ: Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies. J Pharmacol Exp Ther 268:359-365, 1994
116. Valentino RJ, Page ME, Curtis AL: Activation of noradrenergic locus coeruleus neurons by hemodynamic stress is due to local release of corticotropin-releasing factor. Brain Res 555:25-34, 1991
117. Emoto H, Koga C, Ishii H, Yokoo H, Yoshida M, Tanaka M: A CRF antagonist attenuates stress-induced increases in NA turnover in extended brain regions in rats. Brain Res 627:171-176, 1993
118. Lechner SM, Curtis AL, Brons R, Valentino RJ: Locus coeruleus activation by colon distention: role of corticotropin-releasing factor and excitatory amino acids. Brain Res 756:114-124, 1997
119. Curtis AL, Drolet G, Valentino RJ: Hemodynamic stress activates locus coeruleus neurons of unanesthetized rats. Brain Res Bull 31:737-744, 1993
120. Curtis AL, Valentino RJ: Corticotropin-releasing factor neurotransmission in locus coeruleus: a possible site of antidepressant action. Brain Res Bull 35:581-587, 1994
121. Ressler KJ, Nemeroff CB: Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12:2-19, 2000 (suppl 1)
122. Frazer A: Norepinephrine involvement in antidepressant action. J Clin Psychiatry 61:25-30, 2000 (suppl 10)
123. Anand A, Charney DS: Norepinephrine dysfunction in depression. J Clin Psychiatry 61:16-24, 2000 (suppl 10)
124. Stout SC, Owens MJ, Nemeroff CB: Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300:1085-1092, 2002
125. Valentino RJ, Curtis AL: Antidepressant interactions with corticotropin-releasing factor in the noradrenergic nucleus locus coeruleus. Psychopharmacol Bull 27:263-269, 1991
126. Valentino RJ, Curtis AL, Parris DG, Wehby RG: Antidepressant actions on brain noradrenergic neurons. J Pharmacol Exp Ther 253:833-840, 1990
127. Imai H, Steindler DA, Kitai ST: The organization of divergent axonal projections from the midbrain raphe nuclei in the rat. J Comp Neurol 243:363-380, 1986
128. Ma QP, Yin GF, Ai MK, Han JS: Serotonergic projections from the nucleus raphe dorsalis to the amygdala in the rat. Neurosci Lett 134:21-24, 1991
129. Mamounas LA, Molliver ME: Evidence for dual serotonergic projections to neocortex: axons from the dorsal and median raphe nuclei are differentially vulnerable to the neurotoxin p-chloroamphetamine (PCA). Exp Neurol 102:23-36, 1988
130. Mamounas LA, Mullen CA, O'Hearn E, Molliver ME: Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314:558-586, 1991
131. Moore RY, Halaris AE, Jones BE: Serotonin neurons of the midbrain raphe: ascending projections. J Comp Neurol 180:417-438, 1978
132. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF: Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54:129-141, 1996
133. Chaouloff F, Berton O, Mormede P: Serotonin and stress. Neuropsychopharmacology 21:28S-32S, 1999 (suppl 2)
134. Adell A, Casanovas JM, Artigas F: Comparative study in the rat of the actions of different types of stress on the release of 5-HT in raphe nuclei and forebrain areas. Neuropharmacology 36:735-741, 1997
135. Grahn RE, Will MJ, Hammack SE, et al: Activation of serotonin-immunoreactive cells in the dorsal raphe nucleus in rats exposed to an uncontrollable stressor. Brain Res 826:35-43, 1999
136. Maswood S, Barter JE, Watkins LR, Maier SF: Exposure to inescapable but not escapable shock increases extracellular levels of 5-HT in the dorsal raphe nucleus of the rat. Brain Res 783:115-120, 1998
137. Davis M, Shi C: The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann N Y Acad Sci 877:281-291, 1999
138. Amat J, Matus-Amat P, Watkins LR, Maier SF: Escapable and inescapable stress differentially alter extracellular levels of 5-HT in the basolateral amygdala of the rat. Brain Res 812:113-120, 1998
139. Kawahara H, Yoshida M, Yokoo H, Nishi M, Tanaka M: Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci Lett 162:81-84, 1993
140. Hammack SE, Richey KJ, Schmid MJ, LoPresti ML, Watkins LR, Maier SF: The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J Neurosci 22:1020-1026, 2002
141. Lowry CA, Rodda JE, Lightman SL, Ingram CD: Corticotropin-releasing factor increases in vitro firing rates of serotonergic neurons in the rat dorsal raphe nucleus: evidence for activation of a topographically organized mesolimbocortical serotonergic system. J Neurosci 20:7728-7736, 2000
142. Spina G, Merlo-Pich E, Akwa Y, et al: Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (Berl) 160:113-121, 2002
143. Koob GF, Thatcher-Britton K: Stimulant and anxiogenic effects of corticotropin releasing factor. Prog Clin Biol Res 192:499-506, 1985
144. Britton KT, Morgan J, Rivier J, Vale W, Koob GF: Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology 86:170-174, 1985
145. Britton KT, Lee G, Dana R, Risch SC, Koob GF: Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci 39:1281-1286, 1986
146. Swerdlow NR, Geyer MA, Vale WW, Koob GF: Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 88:147-152, 1986
147. Liang KC, Melia KR, Miserendino MJ, Falls WA, Campeau S, Davis M: Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 12:2303-2312, 1992
148. Dunn AJ, File SE: Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav 21:193-202, 1987
149. Jones DN, Kortekaas R, Slade PD, Middlemiss DN, Hagan J J JJ: The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology (Berl) 138:124-132, 1998
150. Moreau JL, Kilpatrick G, Jenck F: Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport 8:1697-1701, 1997
151. Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A: Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 100:207-215, 1999
152. Swiergiel AH, Dunn AJ: CRF-deficient mice respond like wild-type mice to hypophagic stimuli. Pharmacol Biochem Behav 64:59-64, 1999
153. Estibeiro P, Godfray J: Antisense as a neuroscience tool and therapeutic agent. Trends Neurosci 24:S56-S62, 2001 (suppl 11)
154. Skutella T, Montkowski A, Stohr T, et al: Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol 14:579-588, 1994
155. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW: Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 14:2579-2584, 1994
156. Heinrichs SC, Lapsansky J, Lovenberg TW, De Souza EB, Chalmers DT: Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 71:15-21, 1997
157. Skutella T, Probst JC, Renner U, Holsboer F, Behl C: Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 85:795-805, 1998
158. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ: Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 294:588-597, 2000
159. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, Nagayama H: Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 33:189-193, 2000
160. Maciag CM, Dent G, Gilligan P, et al: Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology 26:574-582, 2002
161. Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A: Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25:585-600, 2001
162. Griebel G, Perrault G, Sanger DJ: Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl) 138:55-66, 1998
163. Timpl P, Spanagel R, Sillaber I, et al: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1110ee comments]. Nat Genet 19:162-166, 1998
164. Sajdyk TJ, Gehlert DR: Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala. Brain Res 877:226-234, 2000
165. Swiergiel AH, Takahashi LK, Kalin NH: Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res 623:229-234, 1993
166. Bale TL, Contarino A, Smith GW, et al: Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414, 2000
167. Kishimoto T, Radulovic J, Radulovic M, et al: Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419, 2000
168. Coste SC, Kesterson RA, Heldwein KA, et al: Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403-409, 2000
169. Vetter DE, Li C, Zhao L, et al: Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet 31:363-369, 2002
170. Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP: Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142, 2001
171. Menard J, Treit D: Lateral and medial septal lesions reduce anxiety in the plus-maze and probe-burying tests. Physiol Behav 60:845-853, 1996
172. Menzaghi F, Heinrichs SC, Merlo-Pich E, Tilders FJ, Koob GF: Involvement of hypothalamic corticotropin-releasing factor neurons in behavioral responses to novelty in rats. Neurosci Lett 168:139-142, 1994
173. Ho SP, Takahashi LK, Livanov V, et al: Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain Res 89:29-40, 2001
174. Ball SG, Buchwald AM, Waddell MT, Shekhar A: Depression and generalized anxiety symptoms in panic disorder. Implications for comorbidity. J Nerv Ment Dis 183:304-308, 1995
175. Casper RC: Depression and eating disorders. Depress Anxiety 8:96-104, 1998 (suppl 1)
176. Levine AS, Morley JE: Stress-induced eating in rats. Am J Physiol 241:R72-R76, 1981
177. Menaker L, Navia JM: Appetite regulation in the rat under various physiological conditions: the role of dietary protein and calories. J Nutr 103:347-352, 1973
178. Krahn DD, Gosnell BA, Levine AS, Morley JE: Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Res 443:63-69, 1988
179. Spina M, Merlo-Pich E, Chan RK, et al: Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 273:1561-1564, 1996
180. Benoit SC, Thiele TE, Heinrichs SC, Rushing PA, Blake KA, Steeley RJ: Comparison of central administration of corticotropin-releasing hormone and urocortin on food intake, conditioned taste aversion, and c-Fos expression. Peptides 21:345-351, 2000
181. Grill HJ, Markison S, Ginsberg A, Kaplan JM: Long-term effects on feeding and body weight after stimulation of forebrain or hindbrain CRH receptors with urocortin. Brain Res 867:19-28, 2000
182. Kotz CM, Wang C, Levine AS, Billington CJ: Urocortin in the hypothalamic PVN increases leptin and affects uncoupling proteins-1 and -3 in rats. Am J Physiol Regul Integr Comp Physiol 282:R546-R551, 2002
183. Wang C, Mullet MA, Glass MJ, Billington CJ, Levine AS, Kotz CM: Feeding inhibition by urocortin in the rat hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol 280:R473-R480, 2001
184. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC: Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr 69:584-596, 1999
185. Ohata H, Suzuki K, Oki Y, Shibasaki T: Urocortin in the ventromedial hypothalamic nucleus acts as an inhibitor of feeding behavior in rats. Brain Res 861:1-7, 2000
186. Shade RE, Blair-West JR, Carey KD, et al: Ingestive responses to administration of stress hormones in baboons. Am J Physiol Regul Integr Comp Physiol 282:R10-R18, 2002
187. Currie PJ, Coscina DV, Bishop C, et al: Hypothalamic paraventricular nucleus injections of urocortin alter food intake and respiratory quotient. Brain Res 916:222-228, 2001
188. Cullen MJ, Ling N, Foster AC, Pelleymounter MA: Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology 142:992-999, 2001
189. Smagin GN, Howell LA, Ryan DH, De Souza EB, Harris RB: The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. Neuroreport 9:1601-1606, 1998
190. Wang C, Kotz CM: Urocortin in the lateral septal area modulates feeding induced by orexin A in the lateral hypothalamus. Am J Physiol Regul Integr Comp Physiol 283:R358-R367, 2002
191. Pelleymounter MA, Joppa M, Carmouche M, et al: Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther 293:799-806, 2000
192. Bradbury MJ, McBurnie MI, Denton DA, Lee KF, Vale WW: Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology 141:2715-2724, 2000
193. Self DW: Neural substrates of drug craving and relapse in drug addiction. Ann Med 30:379-389, 1998
194. Sinha R: How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) 158:343-359, 2001
195. Sarnyai Z, Shaham Y, Heinrichs SC: The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53:209-243, 2001
196. Musto DF: Opium, cocaine, and marijuana in American history. Scientific American 265:40-47, 1991
197. Lima MS, Soares BG, Reisser AA, Farrell M: Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97:931-949, 2002
198. Sarnyai Z, Biro E, Penke B, Telegdy G: The cocaine-induced elevation of plasma corticosterone is mediated by endogenous corticotropin-releasing factor (CRF) in rats. Brain Res 589:154-156, 1992
199. Sarnyai Z, Hohn J, Szabo G, Penke B: Critical role of endogenous corticotropin-releasing factor (CRF) in the mediation of the behavioral action of cocaine in rats. Life Sci 51:2019-2024, 1992
200. DeVries AC, Pert A: Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. Psychopharmacology (Berl) 137:333-340, 1998
201. Richter RM, Weiss F: In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32:254-261, 1999
202. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G: Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 675:89-97, 1995
203. Shaham Y, Erb S, Stewart J: Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev 33:13-33, 2000
204. Erb S, Stewart J: A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress-induced reinstatement of cocaine seeking. J Neurosci 19:RC35(1-16), 1999
205. Lu L, Liu D, Ceng X: Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats. Eur J Pharmacol 415:203-208, 2001
206. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L: Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6:74-80, 1995
207. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, Duman RS: Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74:199-208, 2000
208. Lu L, Liu D, Ceng X, Ma L: Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12:4398-4404, 2000
209. Lu L, Ceng X, Huang M: Corticotropin-releasing factor receptor type I mediates stress-induced relapse to opiate dependence in rats. Neuroreport 11:2373-2378, 2000
210. Musto DF: Alcohol and American history. Scientific American 1996:72-78, 1996
211. George SR, Fan T, Roldan L, Naranjo CA: Corticotropin-releasing factor is altered in brains of animals with high preference for ethanol. Alcohol Clin Exp Res 14:425-429, 1990
212. Rassnick S, Heinrichs SC, Britton KT, Koob GF: Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25-32, 1993
213. Merlo Pich E, Lorang M, Yeganeh M, et al: Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15:5439-5447, 1995
214. Sillaber I, Rammes G, Zimmermann S, et al: Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science 296:931-933, 2002
215. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y: The role of corticotropin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 150:317-324, 2000
216. Bilbo SD, Nelson RJ: Behavioral phenotyping of transgenic and knockout animals: a cautionary tale. Lab Anim (NY) 30:24-29, 2001
217. Crawley JN: Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835:18-26, 1999